Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Rare Diseases topic
No spam. Unsubscribe anytime.
House committee gives "due pass" to bill creating Arizona Rare Disease Advisory Council after patient testimony
Summary
The Arizona House Health & Human Services Committee voted 12‑0 to give House Bill 23‑80 a due‑pass recommendation. Sponsors and patient advocates told lawmakers a formal advisory council would give families affected by rare conditions a state voice on diagnosis, treatment access and insurance issues.
Rep. Hernandez, sponsor of House Bill 23‑80, told the committee HB 23‑80 would create a Rare Disease Advisory Council to educate state agencies and the Legislature on the needs of Arizonans with rare diseases and to make policy recommendations. Testimony at the Jan. 29 hearing included patients, medical providers and patient advocates who described diagnostic delays, high treatment costs and sparse research for thousands of rare conditions.
Dr. Melissa Meyer, a nurse practitioner and patient with stiff‑person syndrome, described years to diagnosis and limited treatment options. “We need a voice in current health care policy to address multiple levels from providers, testing, interventions, medications, research,” she told the committee. Dr. Mindy Burnworth, Arizona ambassador for the Rare Action Network (part of the National Organization for Rare Disorders), said 30 states already have advisory councils and urged Arizona to join them.
Vote and action: Vice Chair Heap moved that HB 23‑80 be returned with a due‑pass recommendation. Secretary Shannon called the roll; the committee voted 12 ayes, 0 nays, 0 present and 0 absent. The committee transcript records Representative Bliss asking for cost estimates and Representative Heap asking for follow‑up material; Representative Grama asked for measurable outcomes from other states and witnesses said they would follow up with NORD materials.
Why it matters: Witnesses said that roughly one in 10 Americans will at some point receive a rare‑disease diagnosis, and that 95% of rare diseases lack an FDA‑approved treatment. Advocates argued the council would provide a single state forum for stakeholders — patients, caregivers, clinicians and insurers — to advise policymakers on diagnosis, coverage, research priorities and outreach.
Committee context and next steps: The bill sponsor told members HB 23‑80 had been filed previously and revised based on stakeholder input. Committee members asked for additional material on costs and measurable outcomes from other states; sponsors and testifiers promised to follow up.
Ending: The committee gave HB 23‑80 a due‑pass recommendation and the bill will move forward for further floor consideration and any necessary appropriations or administrative steps.
